
Mixed Trial Results Underscore Challenges of Adjuvant TKI, IO Regimens in RCC
Despite mixed results with TKI-based approaches in the adjuvant setting for patients with renal cell carcinoma (RCC), further investigation is warranted due to the modest benefit observed with pembrolizumab (Keytruda) and the potential of perioperative …